Live Accenture Plc Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow DURECT CORP

Get SEC filing alerts via email and in your feed for DURECT CORP

DRRX

DURECT CORP

About DURECT CORP

DURECT Corporation is a biopharmaceutical company focused on developing novel therapies for serious liver diseases and other unmet medical needs. Its core programs include the investigational epigenetic regulator larsucosterol for alcohol-associated hepatitis and metabolic liver conditions, as well as proprietary pain management products like POSIMIR. The company leverages strategic collaborations, patent protections, and a specialized manufacturing process to advance its innovative drug candidates.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from DURECT CORP

1
1
DURECT CORP DURECT Corporation Reports Q2 2025 Financial Results, Net Loss Decreases to $2.3 Million

Via official filing (AI summary) | 10 months ago | 0 comments

2
1
DURECT CORP Durect Corporation Reports Q1 2025 Financial Results, Net Loss Improves to $4.2 Million

Via official filing (AI summary) | about 1 year ago | 0 comments

3
1
DURECT CORP DURECT Corporation Reports $8.3 Million Net Loss for Fiscal Year 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

4
1
DURECT CORP DURECT Corporation Reports Q3 2024 Financial Results, Revenue Growth Offset by Net Loss and Liquidity Concerns

Via official filing (AI summary) | over 1 year ago | 0 comments